|
| Tumor type | Drug | Patients | Title | Reference |
|
| Carcinoma, non-small-cell lung | Daratumumab + Atezolizumab | 100 | A study of Daratumumab in combination with atezolizumab compared with atezolizumab alone in participants with previously treated advanced or metastatic nonsmall cell lung cancer | NCT03023423 |
| Plasma cell myeloma | Daratumumab | 28 | Daratumumab in treating patients with multiple myeloma | NCT02944565 |
| Multiple myeloma | Daratumumab | 50 | Study of Daratumumab in multiple myeloma (MM) patients in >VGPR/MRD-positive. | NCT03992170 |
| Multiple myeloma | Daratumumab + dexamethasone | 38 | Efficacy of Daratumumab in patients with relapsed/Refractory myeloma with renal impairment | NCT03450057 |
| Relapsed/Refractory multiple myeloma | Nivolumab-Dara/nivolumab-Dara With low dose of cyclophosphamide | 62 | A phase 2 study of nivolumab combined with Daratumumab with or without low-dose cyclophosphamide in relapsed/refractory multiple myeloma | |
| Lymphoma | Daratumumab | 32 | Phase 2 study to assess the clinical efficacy and safety of Daratumumab in patients with relapsed or refractory natural killer/t cell lymphoma, nasal type | NCT02927925 |
| Relapsed/Refractory multiple myeloma | Daratumumab + ATRA | 60 | A phase 1 and phase 2 study of Daratumumab in combination with all-trans retinoic acid in relapsed/refractory multiple myeloma | NCT02751255 |
| Pancreatic, non-small cell lung or triple negative breast cancers (advanced or metastatic solid tumors) | Nivolumab + Daratumumab | 120 | Phase 1/2 study to evaluate the safety and preliminary efficacy of nivolumab combined with Daratumumab in participants with advanced or metastatic solid tumors | NCT03098550 |
| Smoldering plasma cell myeloma | Isatuximab | 62 | Phase II single arm trial of Isatuximab (SAR650984) in patients with high risk smoldering multiple myeloma | NCT02960555 |
| Plasma cell myeloma | Isatuximab + cemiplimab | 109 | A phase 1/2 study to evaluate safety, pharmacokinetics and efficacy of Isatuximab in combination with cemiplimab in patients with relapsed/refractory multiple myeloma | NCT03194867 |
| Multiple myeloma | Isatuximab + Bendamustine + prednisone | 37 | A phase I/II trial of Isatuximab, bendamustine, and prednisone in pentarefractory multiple myeloma | NCT04083898 |
| Lymphoma | Isatuximab + cemiplimab | 130 | A phase 1/2 open-label, multicenter, safety, preliminary efficacy and pharmacokinetic (PK) study of Isatuximab in combination with other anticancer therapies in participants with lymphoma | NCT03769181 |
| Prostate cancer non-small cell lung cancer | Isatuximab + cemiplimab | 134 | A phase 1/2 open-label, multicenter, safety, preliminary efficacy and pharmacokinetic (PK) study of Isatuximab (SAR650984) in combination with REGN2810, or Isatuximab alone, in patients with advanced malignancies | NCT03367819 |
| Plasma cell myeloma | Isatuximab + lenalidomide + dexamethasone | 60 | A phase 1b study of SAR650984 (Anti-CD38 mAb) in combination with lenalidomide and dexamethasone for the treatment of relapsed or refractory multiple myeloma | NCT01749969 |
| Plasma cell myeloma | Isatuximab + lenalidomide + dexamethasone | 89 | A phase 1b study of SAR650984 (isatuximab) in combination with pomalidomide and dexamethasone for the treatment of relapsed/refractory multiple myeloma | NCT02283775 |
|
